Cross-Serotype Protection of a PstS-YidR Fusion mRNA Vaccine Against Systemic Infection and Endogenous Endophthalmitis Caused by Hypervirulent Klebsiella pneumoniae
Pathogens · 2026
DOI: 10.3390/pathogens15090938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Jiaying Lei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Endophthalmitis, Klebsiella Infections, Bacterial Vaccines. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Beijing Public Health High-level Talent Training Program, Beijing Public Health High-level Talent Training Program.
Abstract (Originalsprache)
Background
Hypervirulent Klebsiella pneumoniae (K. pneumoniae) easily causes bacteremia and liver abscess, and invades the eye via blood circulation to trigger blinding endogenous endophthalmitis. Widespread multidrug resistance limits antibiotic treatment, while traditional capsular polysaccharide vaccines cannot provide cross-serotype protection.
Methods
We established a mouse model of intraperitoneal infection-induced endogenous endophthalmitis. BALB/c mice received two intramuscular injections of LNP-encapsulated PstS-YidR fusion mRNA vaccine, followed by challenge with hypervirulent K1 or K2 strains. We monitored body weight, quantified multi-tissue bacterial loads, detected IL-1β, IL-6 and TNF-α, and performed slit-lamp observation and liver/ocular histopathology.
Results
The vaccine relieved systemic symptoms and weight loss, suppressed bacterial dissemination across peritoneal, blood, liver, lung and eye tissues, and reduced excessive inflammatory factor release. It alleviated intraocular suppurative lesions, preserved ocular structure, and mitigated liver abscess and hepatocellular necrosis, with equal protective efficacy against K1 and K2 and favorable in vivo safety.
Conclusions
The PstS-YidR fusion mRNA vaccine blocks systemic spread and intraocular invasion of hypervirulent K. pneumoniae and alleviates multi-organ inflammatory damage. It serves as a safe candidate vaccine for preventing K1/K2-type hypervirulent Klebsiella infections and endogenous endophthalmitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China.
- Nanjing Chengshi (TheraRNA) Biomedical Technology Co., Ltd., Nanjing 210000, China.
ORCID-Profile: Tiyun Han
Förderung
- the Beijing Public Health High-level Talent Training Program
- Beijing Public Health High-level Talent Training Program
Zitieren
APA
Lei, J., Lu, X., Han, T., Jin, Z., & Liang, Q. (2026). Cross-Serotype Protection of a PstS-YidR Fusion mRNA Vaccine Against Systemic Infection and Endogenous Endophthalmitis Caused by Hypervirulent Klebsiella pneumoniae. Pathogens. https://doi.org/10.3390/pathogens15090938
Vancouver
Lei J, Lu X, Han T, Jin Z, Liang Q. Cross-Serotype Protection of a PstS-YidR Fusion mRNA Vaccine Against Systemic Infection and Endogenous Endophthalmitis Caused by Hypervirulent Klebsiella pneumoniae. Pathogens. 2026. doi:10.3390/pathogens15090938
BibTeX
@article{Lei2026,
author = {Lei, Jiaying and Lu, Xinxin and Han, Tiyun and Jin, Zibing and Liang, Qingfeng},
title = {Cross-Serotype Protection of a PstS-YidR Fusion mRNA Vaccine Against Systemic Infection and Endogenous Endophthalmitis Caused by Hypervirulent Klebsiella pneumoniae},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15090938}
}
EUVIMED